Hutchmed (China) (HKG:0013) obtained conditional approval from China's National Medical Product Association for Tazemetostat as a treatment for patients with relapsed or refractory follicular lymphoma (FL) with EZH2 mutation who have received at least two systemic therapies.
Tazemetostat, sold under the brand name Tazverik, is a first-in-class methyltransferase inhibitor of EZH2. Іt is approved by the US FDA for the treatment of certain patients with R/R FL and certain patients with advanced epithelioid sarcoma, according to a Friday filing with the Hong Kong bourse.
The drugmaker's shares were down almost 3% in Monday's afternoon trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。